In particular, the pharmacological dual inhibition of PDGFR-β and VEGFR-2 reduces GBM vascularization in GBM mouse models and improves animal survival, mainly interfering with the EndoMT process of tumor-derived ECs, which exhibit resistance to anti-VEGF/VEGFR-2 treatment [126]. The gene discussed is KDR; the disease is neoplasm.